Literature DB >> 9691759

Control of the immune response by DHEA and its metabolites.

R M Loria1, D A Padgett.   

Abstract

The 17 keto steroid, Dehydroepiandrosterone (5-androsten-3 beta-17-one, DHEA) has been shown to protect mice from a variety of lethal infections. This includes, but is not limited to, infection with viruses (herpesvirus type 2, coxsackievirus B4-CVB4),bacteria (Enterococcus faecalis, Pseudomonas aeruginosa), and a parasite (Cryptosporidium parvum). We have reported that androstenediol (5-androsten-3 beta-17 beta-diol, beta AED), which is derived from DHEA, is at least 100x more effective in up-regulating systemic resistance against CVB4-infection than its precursor. Furthermore, androstenetriol (5-androstene-3 beta-7 beta-17 beta-triol beta AET) which is formed by 7 beta hydroxylation of beta AED, was more effective against CVB4-infection than its precursor beta AED. Neither steroid however has shown any significant direct antiviral effects. The in-vitro influences of DHEA, beta AED, and beta AET on a mitogen-induced mixed splenocyte proliferation assay were determined. The results showed that DHEA suppressed the proliferation of concanavalin A (Con A) or lipopolysaccharide (LPS) activated cultures in a dose dependent manner. beta AED had little influence on the activation response. However, beta AET potentiated the response to both mitogens significantly above control. The regulation of interleukin-2 and interleukin-3 secretion from Con A-activated lymphocytes was analogous to these observations. These functions were suppressed by DHEA, unaffected by beta AED, and potently increased by beta AET. Moreover, the classic immuno-suppressive effects of hydro-cortisone on Con A-induced lymphocyte proliferation, as well as IL-2 and IL-3 production were unaffected by co-cultured with DHEA and only minimally counteracted by beta AED. In contrast, beta AET significantly counteracted the effect of hydrocortisone when co-cultured together. These results show that while in-vivo, DHEA, beta AED, and beta AET each function in a similar manner. In-vitro, their effects are dramatically different from one another with only beta AET potentiating the cellular response by increasing lymphocyte activation and counteracting the immuno-suppressive activity of hydrocortisone.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9691759

Source DB:  PubMed          Journal:  Rinsho Byori        ISSN: 0047-1860


  5 in total

1.  Phase I and Phase II clinical trials of androst-5-ene-3β,7β,17β-triol.

Authors:  Dwight R Stickney; Clarence N Ahlem; Elizabeth Morgan; Christopher L Reading; Nanette Onizuka; James M Frincke
Journal:  Am J Transl Res       Date:  2011-04-12       Impact factor: 4.060

2.  Studies of the pharmacology of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol, a synthetic anti-inflammatory androstene.

Authors:  Clarence N Ahlem; Michael R Kennedy; Theodore M Page; Christopher L Reading; Steven K White; John J McKenzie; Phaedra I Cole; Dwight R Stickney; James M Frincke
Journal:  Int J Clin Exp Med       Date:  2011-04-23

3.  Study of the impact of long-duration space missions at the International Space Station on the astronaut microbiome.

Authors:  Alexander A Voorhies; C Mark Ott; Satish Mehta; Duane L Pierson; Brian E Crucian; Alan Feiveson; Cherie M Oubre; Manolito Torralba; Kelvin Moncera; Yun Zhang; Eduardo Zurek; Hernan A Lorenzi
Journal:  Sci Rep       Date:  2019-07-09       Impact factor: 4.379

4.  Effects of dehydroepiandrosterone on Th2 cytokine production in peripheral blood mononuclear cells from asthmatics.

Authors:  Inseon S Choi; Yong Cui; Young Ah Koh; Hyun Chul Lee; Yong Bum Cho; Young Ho Won
Journal:  Korean J Intern Med       Date:  2008-12       Impact factor: 2.884

5.  A new parasiticidal compound in T. solium cysticercosis.

Authors:  Romel Hernández-Bello; Galileo Escobedo; Julio Cesar Carrero; Claudia Cervantes-Rebolledo; Charles Dowding; James Frincke; Chris Reading; Jorge Morales-Montor
Journal:  Biomed Res Int       Date:  2012-12-20       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.